// App-Quantinova.ai

P5-06-06 : Clinically significant changes of receptors status (ER, PR and HER2) after receiving neoadjuvant chemotherapy (NACT) in breast cancer (BC) predicts the prognosis and guides the choice of the optimal adjuvant therapy (AT): Retesting of the receptor status should be mandatory

Researchers

Presenter

  • Tarek M. a. Abdel-Fatah

Principal Investigators

  • Rebekah Webb

  • Jennifer Walker

  • Jun Lim

  • A. Graham Pockley

  • Graham Ball

  • Matthew Griffiths

  • Ian Ellis

  • Emad Rakhah

  • Zsolt Hodi

  • Andrew Lee

  • Arlene Chan

  • Stephen Chan

Medical Centers

  • Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom

  • John van Geest Cancer Research Centre, School of Science and Technology, Nottingham, United Kingdom

  • School of Science and Technology, Nottingham Trent University, Nottingham, Canada

  • Histopathology Department, Nottingham City Hospital, Nottingham, Nottingham, United Kingdom

  • Breast Cancer Research Centre - WA & Curtin University, Perth, Australia

Locations

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Proliferation marker protein Ki-67

  • Sperm Associated Antigen 5

Drug/Treatment

  • Trastuzumab

  • taxane

Outcome

  • N/A

Study Design

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved